Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, McHugh, J, Jones, AB, Karlsson, Q, Merson, S, Ong, KR, Hoffman, J, Huber, C, Maehle, L, Grindedal, EM, Stormorken, A, Evans, DG, Rothwell, J, Lalloo, F, Brady, AF, Bartlett, M, Snape, K, Hanson, H, James, P, McKinley, J, Mascarenhas, L, Syngal, S, Ukaegbu, C, Side, L, Thomas, T, Barwell, J, Teixeira, MR, Izatt, L, Suri, M, Macrae, FA, Poplawski, N, Chen-Shtoyerman, R, Ahmed, M, Musgrave, H, Nicolai, N, Greenhalgh, L, Brewer, C, Pachter, N, Spigelman, AD, Azzabi, A, Helfand, BT, Halliday, D, Buys, S, Cajal, TRY, Donaldson, A, Cooney, KA, Harris, M, McGrath, J, Davidson, R, Taylor, A, Cooke, P, Myhill, K, Hogben, M, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Dias, A, Dudderidge, T, Eccles, DM, Green, K, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lilja, H, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, AV, Moynihan, C, Raghallaigh, HN, Rennert, G, Collier, R, Offman, J, Kote-Jarai, Z, Eeles, RA. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. LANCET ONCOLOGY. 2021; 22(11)DOI:10.1016/S1470-2045(21)00522-2. PMID:34678156. IF:54.433(Q1/1D).

Kim, SJ, Lubinski, J, Huzarski, T, Moller, P, Armel, S, Karlan, BY, Senter, L, Eisen, A, Foulkes, WD, Singer, CF, Tung, N, Bordeleau, L, Neuhausen, SL, Olopade, OI, Eng, C, Weitzel, JN, Fruscio, R, Narod, SA, Kotsopoulos, J, Cajal, T.R., Trister, Rachel. Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2021; 30(11)DOI:10.1158/1055-9965.EPI-21-0296. PMID:34426412. IF:4.090(Q2/4D).

Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Álava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., López Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., EURACAN, GENTURIS and ERN PaedCan. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2021; 32(12)DOI:10.1016/j.annonc.2021.08.1995. PMID:34500044. IF:51.769(Q1/1D).

Serna, N, Carratala, JV, Conchillo-Sole, O, Martinez-Torro, C, Unzueta, U, Mangues, R, Ferrer-Miralles, N, Daura, X, Vazquez, E, Villaverde, A. Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4. Pharmaceutics. 2021; 13(11)DOI:10.3390/pharmaceutics13111922. PMID:34834337. IF:6.525(Q1/2D).